Compare Atlassian Corporation PLC (TEAM) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atlassian Corporation PLC vs TransMedics Group Inc — how do they compare? Atlassian Corporation PLC trades at $204.3 (market cap $51.53B), while TransMedics Group Inc trades at $79.31 (market cap $2.74B). The key difference: Atlassian Corporation PLC is far larger — about 18.8× TransMedics Group Inc's market cap, and Atlassian Corporation PLC is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Atlassian Corporation PLC for 64 Days and TransMedics Group Inc for 24 Days on average.
| TEAM | TMDX | |
|---|---|---|
Market Cap | $51.53B | $2.74B |
Volume | 2,904,511 | 949,331 |
Sector | Technology | Health |
52-Week High | $203.57 | $150.42 |
52-Week Low | $57.15 | $61.99 |
Typical Hold Time | 64 Days | 24 Days |
Enterprise Value | $51.52B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atlassian (TEAM) trades at $195.67, up 0.87% with bullish technical signals and strong analyst support. The stock shows improving fundamentals with revenue growth from $2.8B in 2022 to $5.22B in 2025, though net margins remain negative. Recent earnings beats and AI-driven cloud adoption provide momentum, with the current price near resistance at $196.
Outlook remains positive given robust cloud growth and AI integration, but high valuations and persistent losses pose risks. Wall Street consensus is strongly bullish with 30 buy ratings and a $191.16 target, though the stock trades above this level. Key risks include execution challenges and competitive pressures in the enterprise software space.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
